Week of July 16, 2012: Bristol-Myers Squibb Begins Tender Offer to Acquire Amylin Pharmaceuticals; FDA Approves Gilead's Truvada for Reducing the Risk of Acquiring HIV; and More - Pharmaceutical

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of July 16, 2012: Bristol-Myers Squibb Begins Tender Offer to Acquire Amylin Pharmaceuticals; FDA Approves Gilead's Truvada for Reducing the Risk of Acquiring HIV; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

BioStorage Technologies, a provider of sample-management solutions for the bioscience industry, including storage, cold-chain logistics, and virtual sample intelligence, is expanding its services to the Asia Pacific region. The expansion includes the appointment of Jason Huang as general manager of the region. BioStorage Technologies Asia Pacific will be headquartered in Singapore and will provide technical consulting in addition to a range of sample-management capabilities. Huang will be responsible for overseeing and managing the operations in Asia, identifying and developing new services, and driving overall business development and services growth in the region. Read More

Bristol-Myers Squibb (BMS) has begun a cash tender offer to purchase all outstanding shares of common stock of Amylin Pharmaceuticals. Upon the successful closing of the tender offer, stockholders of Amylin will receive $31.00 in cash for each share of Amylin common stock validly tendered and not validly withdrawn in the offer, without interest and less any applicable withholding taxes. Following the purchase of shares in the tender offer, Amylin will become a subsidiary of BMS. BMS had previously announced its intention to acquire Amylin on June 29, 2012. Read More

FDA has approved Gilead Sciences’s once-daily oral Truvada (emtricitabine; tenofovir disoproxil fumarate), a treatment to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. As part of the approval, Gilead worked with the FDA to develop a Risk Evaluation and Mitigation Strategy to help ensure safe use of Truvada for pre-exposure prophylaxis as part of a comprehensive prevention strategy. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here